The sodium glucose cotransporter 2 (sglt2) inhibitors global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size -
The
sodium glucose cotransporter 2 (SGLT2) inhibitors market size has grown
strongly in recent years. It will grow from $9.37 billion in 2023 to
$10.17 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%.
The growth in the historic period can be attributed to early clinical
trial successes, rising regulatory approvals, increasing diabetes
diagnosis rates, and the demand for innovative diabetes treatments.
The sodium glucose cotransporter 2 (SGLT2) inhibitors market size is expected to see strong growth in the next few years. It will grow to $14.19 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing obesity rates, growing awareness of diabetes management, and expanding applications in heart and kidney disease treatments. Major trends in the forecast period include the integration of combination therapies, personalized medicine approaches, technological improvement, and traditional drug development.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report
Scope Of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
The Business Research Company's reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
Market Drivers -
The
increasing prevalence of diabetes is expected to propel the growth of
the sodium glucose cotransporter 2 (SGLT2) inhibitor market going
forward. Diabetes refers to a group of metabolic disorders characterized
by high blood sugar levels resulting from defects in insulin secretion,
insulin action, or both. The rise in diabetes cases can be attributed
to factors such as urbanization, stress, environmental pollutants, and a
lack of access to healthcare services. Sodium glucose cotransporter 2
(SGLT2) inhibitors are used in diabetes treatment to lower blood glucose
levels by preventing glucose reabsorption in the kidneys, leading to
its excretion in urine. They also offer cardiovascular and renal
benefits, making them a valuable option for managing diabetes and its
complications. For instance, in July 2021, according to the
International Diabetes Federation, a Belgium-based national diabetes
association, the total number of people living with diabetes is expected
to increase to 643 million by 2030 and 783 million by 2045. Three out
of four adults with diabetes reside in low- and middle-income countries.
Therefore, the increasing prevalence of diabetes is driving the growth
of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.
Market Trends -
Major
companies operating in the sodium glucose cotransporter 2 (SGLT2)
inhibitor market are focused on developing dual inhibitor therapeutic
solutions to improve patient outcomes and manage blood sugar levels.
Dual inhibitor therapeutic solutions refer to treatments that
simultaneously target two different sodium-glucose cotransporters (SGLT1
and SGLT2) to enhance efficacy in managing conditions such as heart
failure and diabetes. For instance, in May 2023, Lexicon Pharmaceuticals
Inc., a US-based biopharmaceutical company, received approval from the
Food and Drug Administration (FDA) for sotagliflozin, a treatment for
heart failure. This first-in-class dual inhibitor of sodium-glucose
cotransporters 1 and 2 is a once-daily tablet designed to reduce
cardiovascular death, heart failure hospitalizations, and urgent heart
failure visits in adults with heart failure, type 2 diabetes, chronic
kidney disease, and other cardiovascular risk factors. Its benefits
include reduced renal glucose and sodium reabsorption, which leads to
preload and afterload reduction and decreased sympathetic activity.
The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –
1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics
Get an inside scoop of the sodium glucose cotransporter 2 (sglt2) inhibitors market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp
Regional Insights -
North
America was the largest region in the sodium glucose cotransporter 2
(SGLT2) inhibitors market in 2023. Asia-Pacific is expected to be the
fastest-growing region in the forecast period. The regions covered in
the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are
Asia-Pacific, Western Europe, Eastern Europe, North America, South
America, Middle East, Africa.
Key Companies -
Major companies
operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors
market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co.
Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca
plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH,
Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical
Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho
Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark
pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei
Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki pharmaceutical Co
Ltd.
Table of Contents
1. Executive Summary
2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report Structure
3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Trends And Strategies
4. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market – Macro Economic Scenario
5. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Size And Growth
…..
27. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment